CoChat

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia

Karnes, Jason H., Rollin, Jerome, Giles, Jason B., Martinez, Kiana L., Steiner, Heidi E., Shaffer, Christian M., Momozawa, Yukihide, Inai, Chihiro, Bombin, Andrei, Shi, Mingjian, Mosley, Jonathan D., Stanaway, Ian, Selleng, Kathleen, Thiele, Thomas, Mushiroda, Taisei, Pouplard, Claire, Heddle, Nancy M., Kubo, Michiaki, Phillips, Elizabeth J., Warkentin, Theodore E., Gruel, Yves, Greinacher, Andreas, Roden, Dan M. · 2022 · Blood
Cited by 18

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with positive functional assay as the outcome in a large discovery cohort of patients divided into 3 groups: (1) functional assay-positive cases (n = 1269), (2) antibody-positive (functional assay-negative) controls (n = 1131), and (3) antibody-negative controls (n = 1766). Significant associations (α = 5 × 10−8) were investigated in a replication cohort (α = 0.05) of functional assay-confirmed HIT cases (n = 177), antibody-positive (function assay-negative) controls (n = 258), and antibody-negative controls (n = 351). We observed a strong association for positive functional assay with increasing PF4/heparin immunoglobulin-G (IgG) level (odds ratio [OR], 16.53; 95% confidence interval [CI], 13.83-19.74; P = 1.51 × 10−209) and female sex (OR, 1.15; 95% CI, 1.01-1.32; P = .034). The rs8176719 C insertion variant in ABO was significantly associated with positive functional assay status in the discovery cohort (frequency = 0.41; OR, 0.751; 95% CI, 0.682-0.828; P = 7.80 × 10−9) and in the replication cohort (OR, 0.467; 95% CI, 0.228-0.954; P = .0367). The rs8176719 C insertion, which encodes all non-O blood group alleles, had a protective effect, indicating that the rs8176719 C deletion and the O blood group were risk factors for HIT (O blood group OR, 1.42; 95% CI, 1.26-1.61; P = 3.09 × 10−8). Meta-analyses indicated that the ABO association was independent of PF4/heparin IgG levels and was stronger when functional assay-positive cases were compared with antibody-positive (functional assay-negative) controls than with antibody-negative controls. Sequencing and fine-mapping of ABO demonstrated that rs8176719 was the causal single nucleotide polymorphism (SNP). Our results clarify the biology underlying HIT pathogenesis with ramifications for prediction and may have important implications for related conditions, such as vaccine-induced thrombotic thrombocytopenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021014240

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 49

  1. Greinacher, 2015, CLINICAL PRACTICE. Heparin-induced thrombocytopenia, N Engl J Med., 373, 252, 10.1056/NEJMcp1411910 · DOI · Paper page
  2. Cuker, 2018, American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia, Blood Adv., 2, 3360, 10.1182/bloodadvances.2018024489 · DOI · Paper page
  3. Girolami, 2003, The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study, Blood., 101, 2955, 10.1182/blood-2002-07-2201 · doi:10.1182/blood-2002-07-2201
  4. Greinacher, 2005, Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients, Thromb Haemost., 94, 132
  5. Linkins, 2012, Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, e495S
  6. Vayne, 2021, PF4 Immunoassays in vaccine-induced thrombotic thrombocytopenia, N Engl J Med., 385, 376, 10.1056/NEJMc2106383 · DOI
  7. Scully, 2021, Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination, N Engl J Med., 384, 2202, 10.1056/NEJMoa2105385 · DOI · Paper page
  8. Karnes, 2018, Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?, Pharmacogenomics., 19, 1413, 10.2217/pgs-2018-0147 · doi:10.2217/pgs-2018-0147
  9. Arepally, 2017, Heparin-induced thrombocytopenia, Blood., 129, 2864, 10.1182/blood-2016-11-709873 · DOI · Paper page
  10. Khandelwal, 2016, Immune pathogenesis of heparin-induced thrombocytopenia, Thromb Haemost., 116, 792, 10.1160/TH16-01-0074 · DOI
  11. Witten, 2018, Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study, J Mol Med (Berl)., 96, 765, 10.1007/s00109-018-1661-6 · DOI
  12. Karnes, 2015, A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record, Thromb Haemost., 113, 772, 10.1160/TH14-08-0670 · DOI
  13. Gruel, 2020, Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature, Thromb Haemost., 120, 1096, 10.1055/s-0040-1712957 · DOI
  14. Rollin, 2015, Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2, Blood., 125, 2397, 10.1182/blood-2014-09-594515 · DOI
  15. Eekels, 2019, An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia, J Thromb Haemost., 17, 525, 10.1111/jth.14383 · DOI
  16. Greinacher, 1994, Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay, Transfusion., 34, 381, 10.1046/j.1537-2995.1994.34594249047.x · doi:10.1046/j.1537-2995.1994.34594249047.x
  17. Lo, 2006, Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings, J Thromb Haemost., 4, 759, 10.1111/j.1538-7836.2006.01787.x · doi:10.1111/j.1538-7836.2006.01787.x
  18. Greinacher, 2010, Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests, J Thromb Haemost., 8, 2025, 10.1111/j.1538-7836.2010.03974.x · doi:10.1111/j.1538-7836.2010.03974.x
  19. Abecasis, 2010, A map of human genome variation from population-scale sequencing, Nature., 467, 1061, 10.1038/nature09534 · DOI · Paper page
  20. Pritchard, 2000, Inference of population structure using multilocus genotype data, Genetics., 155, 945, 10.1093/genetics/155.2.945 · DOI · Paper page
  21. Yang, 2013, Genome-wide complex trait analysis (GCTA): methods, data analyses, and interpretations, Methods Mol Biol., 1019, 215, 10.1007/978-1-62703-447-0_9 · DOI · Paper page
  22. Momozawa, 2016, Low-frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population, Hum Mol Genet., 25, 5027
  23. Kichaev, 2014, Integrating functional data to prioritize causal variants in statistical fine-mapping studies, PLoS Genet., 10, e1004722, 10.1371/journal.pgen.1004722 · DOI · Paper page
  24. Watanabe, 2017, Functional mapping and annotation of genetic associations with FUMA, Nat Commun., 8, 1826, 10.1038/s41467-017-01261-5 · DOI · Paper page
  25. Vasan, 2016, ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors, Circulation., 133, 1449, 10.1161/CIRCULATIONAHA.115.017563 · DOI · Paper page
  26. Groot, 2020, Genetically determined ABO blood group and its associations with health and disease, Arterioscler Thromb Vasc Biol., 40, 830, 10.1161/ATVBAHA.119.313658 · DOI · Paper page
  27. Kolin, 2020, Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank, PLoS One., 15, e0241264, 10.1371/journal.pone.0241264 · DOI · Paper page
  28. Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet., 81, 559, 10.1086/519795 · DOI · Paper page
  29. Wang, 2010, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data, Nucleic Acids Res., 38, e164, 10.1093/nar/gkq603 · DOI · Paper page
  30. Kircher, 2014, A general framework for estimating the relative pathogenicity of human genetic variants, Nat Genet., 46, 310, 10.1038/ng.2892 · DOI · Paper page
  31. Goumidi, 2021, Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation, Blood., 137, 2394, 10.1182/blood.2020008997 · DOI
  32. Hubbard, 2020, FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity, J Exp Med., 217, e20200359, 10.1084/jem.20200359 · DOI · Paper page
  33. Lande, 2019, CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis, Nat Commun., 10, 1731, 10.1038/s41467-019-09683-z · DOI
  34. Greinacher, 2007, Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes, J Thromb Haemost., 5, 1666, 10.1111/j.1538-7836.2007.02617.x · doi:10.1111/j.1538-7836.2007.02617.x
  35. Warkentin, 2008, Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays, J Thromb Haemost., 6, 1304, 10.1111/j.1538-7836.2008.03025.x · doi:10.1111/j.1538-7836.2008.03025.x
  36. Kiechl, 2011, Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis, Circ Cardiovasc Genet., 4, 681, 10.1161/CIRCGENETICS.111.960682 · DOI · Paper page
  37. Larson, 2016, ABO blood group associations with markers of endothelial dysfunction in the multi-ethnic study of atherosclerosis, Atherosclerosis., 251, 422, 10.1016/j.atherosclerosis.2016.05.049 · DOI
  38. Fareed, 1999, Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation, Semin Thromb Hemost., 25, 37
  39. Campello, 2018, Activated platelet-derived and leukocyte-derived circulating microparticles and the risk of thrombosis in heparin-induced thrombocytopenia: a role for PF4-bearing microparticles?, Cytometry B Clin Cytom., 94, 334, 10.1002/cyto.b.21507 · doi:10.1002/cyto.b.21507
  40. Albánez, 2016, Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms, J Thromb Haemost., 14, 953, 10.1111/jth.13294 · DOI
  41. Johnston, 2020, Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation, Blood., 135, 1270, 10.1182/blood.2018881607 · DOI
  42. Simpson, 2021, First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland, Nat Med., 27, 1290, 10.1038/s41591-021-01408-4 · DOI · Paper page
  43. Brodard, 2021, COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies, J Thromb Haemost., 19, 1294, 10.1111/jth.15262 · DOI
  44. Huynh, 2021, Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia, Nature., 596, 565, 10.1038/s41586-021-03744-4 · DOI · Paper page
  45. COVID-19 Host Genetics Initiative, 2021, Mapping the human genetic architecture of COVID-19, Nature., 600, 472, 10.1038/s41586-021-03767-x · DOI · Paper page
  46. Ellinghaus, 2020, Genomewide association study of severe COVID-19 with respiratory failure, N Engl J Med., 383, 1522, 10.1056/NEJMoa2020283 · DOI · Paper page
  47. Daviet, 2020, Heparin-induced thrombocytopenia in severe COVID-19, Circulation., 142, 1875, 10.1161/CIRCULATIONAHA.120.049015 · DOI
  48. Hodonsky, 2020, Ancestry-specific associations identified in genome-wide combined-phenotype study of red blood cell traits emphasize benefits of diversity in genomics, BMC Genomics., 21, 228, 10.1186/s12864-020-6626-9 · DOI
  49. Garratty, 2004, ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States, Transfusion., 44, 703, 10.1111/j.1537-2995.2004.03338.x · DOI · Paper page

Cited by

See all 18

Metadata

Authors
Karnes, J. H., Rollin, J., Giles, J. B., Martinez, K. L., Steiner, H. E., Shaffer, C. M., Momozawa, Y., Inai, C., Bombin, A., Shi, M., Mosley, J. D., Stanaway, I., Selleng, K., Thiele, T., Mushiroda, T., Pouplard, C., Heddle, N. M., Kubo, M., Phillips, E. J., Warkentin, T. E., Gruel, Y., Greinacher, A., & Roden, D. M.
Affiliations
  • 1Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, AZ;
  • 3Regional University Hospital Centre Tours, Department of Hemostasis, Tours, France;
  • 5Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;
  • 6RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan;
  • 2Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN;
  • 7Department of Medicine, Kidney Research Institute, University of Washington, Seattle, WA;
  • 8Institute of Immunology and Transfusion Medicine, University of Greifswald, Greifswald, Germany;
  • 9Department of Medicine, McMaster University, Hamilton, ON, Canada; and
Venue
Blood
Published
2022-07-21
Volume
140
Issue
3
Pages
274-284
ISSN
  • 0006-4971
  • 1528-0020
Cited by
18
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. https://app.cochat.ai/papers/10.1182/blood.2021014240
The paper
Karnes, J. H., Rollin, J., Giles, J. B., Martinez, K. L., Steiner, H. E., Shaffer, C. M., Momozawa, Y., Inai, C., Bombin, A., Shi, M., Mosley, J. D., Stanaway, I., Selleng, K., Thiele, T., Mushiroda, T., Pouplard, C., Heddle, N. M., Kubo, M., Phillips, E. J., . . . Roden, D. M. (2022). ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood. https://doi.org/10.1182/blood.2021014240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.